A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

Clinical trial NCT02698189 · TERMINATED

Trial details

NCT number: NCT02698189
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

AML Including AML de Novo and AML Secondary to MDS DLBCL

Start date: 2016-05-19
Primary completion: 2018-01-18
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.